Review finds endocannabinoid system alterations in fibromyalgia and some promise for cannabinoid treatments

Clinical evidence shows endocannabinoid system alterations in fibromyalgia patients, including single nucleotide polymorphisms and increased circulating endocannabinoids. FAAH inhibition (boosting anandamide) showed promise in the reserpine-induced myalgia animal model. Cannabis and cannabinoid treatments reduced pain and anxiety in clinical studies, but methodological limitations prevent treatment recommendations.

Comprehensive review of preclinical and clinical studies examining the endocannabinoid system in fibromyalgia, covering animal models, genetic studies, biomarker measurements, and treatment trials with cannabis-based medicines.

Fibromyalgia remains a significant unmet clinical need, and evidence that the endocannabinoid system is altered in these patients provides a biological rationale for cannabinoid-based treatments beyond symptom management.

The identification of endocannabinoid system alterations in fibromyalgia patients moves the field beyond simply asking "does cannabis help pain?" toward understanding why specific patients might benefit from cannabinoid-targeting therapies.

Existing clinical studies have methodological limitations including small samples and short durations. Animal models have limited validity for the full fibromyalgia phenotype. Sex bias in preclinical research (fibromyalgia primarily affects women). No long-term efficacy or safety data.